Search company, investor...

Predict your next investment

Holding Company
FINANCE | Investment Firms & Funds
novoholdings.dk

Investments

271

Portfolio Exits

59

Partners & Customers

2

Service Providers

3

About Novo Holdings

Novo Holdings is the holding company of the Novo Group and manages the investment assets of the Novo Nordisk Foundation. It invests in life science companies at all stages of development and in a broad portfolio of equity and fixed-income securities. Novo Holdings was formerly known as Novo. The company was founded in 1999 and is based in Hellerup, Denmark.

Headquarters Location

Tuborg Havnevej 19

Hellerup, 2900,

Denmark

+45 3527 6500

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Novo Holdings News

Doctor Anywhere raises $41m in Series C1 extension round

Dec 7, 2023

Photo: Doctor Anywhere 07 December, 2023 Singapore-based healthcare company Doctor Anywhere (DA) has raised $40.8 million in a Series C1 extension round from investors including Square Peg and Novo Holdings, according to an announcement on Thursday. In Dec 2022, the firm had raised a Series C1 funding round of $38.8 million, led by Novo Holdings and backed by existing shareholders including Asia Partners, Kamet Capital, Square Peg, IHH Healthcare, EDBI, and OSK-SBI Venture Partners. The Series C1 round came after the healthtech startup raised a $65.7 million Series C in August 2021. The funds from the latest financing will be used to drive next-generation healthcare innovation within the company, and to deepen its presence in secondary care. The company will intensify product innovation in building a vertically integrated digital healthcare ecosystem. This ecosystem will cater to the rising demand for healthcare services.

Novo Holdings Investments

271 Investments

Novo Holdings has made 271 investments. Their latest investment was in Doctor Anywhere as part of their Series C - III on December 12, 2023.

CBI Logo

Novo Holdings Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/6/2023

Series C - III

Doctor Anywhere

$40.8M

No

Square Peg Ventures, and Undisclosed Investors

2

12/4/2023

Unattributed

energyRe

Yes

2

11/15/2023

Series B

NMD Pharma

$80M

No

3

11/2/2023

Series B

Subscribe to see more

$99M

Subscribe to see more

10

10/11/2023

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/6/2023

12/4/2023

11/15/2023

11/2/2023

10/11/2023

Round

Series C - III

Unattributed

Series B

Series B

Series D

Company

Doctor Anywhere

energyRe

NMD Pharma

Subscribe to see more

Subscribe to see more

Amount

$40.8M

$80M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Square Peg Ventures, and Undisclosed Investors

Sources

2

2

3

10

10

Novo Holdings Portfolio Exits

59 Portfolio Exits

Novo Holdings has 59 portfolio exits. Their latest portfolio exit was Altasciences Clinical Research on September 21, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/21/2023

Divestiture

$99M

2

2/9/2023

Reverse Merger

$99M

4

12/29/2022

Reverse Merger

$99M

5

12/12/2022

Acq - Pending

Subscribe to see more

$99M

Subscribe to see more

10

9/28/2022

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/21/2023

2/9/2023

12/29/2022

12/12/2022

9/28/2022

Exit

Divestiture

Reverse Merger

Reverse Merger

Acq - Pending

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

4

5

10

10

Novo Holdings Acquisitions

13 Acquisitions

Novo Holdings acquired 13 companies. Their latest acquisition was Paratek Pharmaceuticals on September 20, 2023.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/20/2023

Debt

$99M

$129.3M

Take Private

10

6/21/2023

$99M

Acquired

10

9/23/2022

Other

$99M

Acquired

1

1/4/2022

Subscribe to see more

$99M

Subscribe to see more

10

1/3/2022

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/20/2023

6/21/2023

9/23/2022

1/4/2022

1/3/2022

Investment Stage

Debt

Other

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$129.3M

Note

Take Private

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

10

10

1

10

10

Novo Holdings Partners & Customers

2 Partners and customers

Novo Holdings has 2 strategic partners and customers. Novo Holdings recently partnered with Industriens Pension, Urban Partners, and DSB Ejendomme on February 2, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

2/7/2023

Partner

Denmark

Novo Holdings · Four partners agree to jointly redevelop Jernbanebyen in Copenhagen

DSB , NREP , Industriens Pension and Novo Holdings have entered into a joint venture agreement to redevelop Jernbanebyen in Copenhagen .

2

11/19/2019

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

2/7/2023

11/19/2019

Type

Partner

Partner

Business Partner

Country

Denmark

United States

News Snippet

Novo Holdings · Four partners agree to jointly redevelop Jernbanebyen in Copenhagen

DSB , NREP , Industriens Pension and Novo Holdings have entered into a joint venture agreement to redevelop Jernbanebyen in Copenhagen .

Subscribe to see more

Subscribe to see more

Sources

2

10

Novo Holdings Service Providers

5 Service Providers

Novo Holdings has 5 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired - II

Counsel

General Counsel

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Acquired - II

Subscribe to see more

Subscribe to see more

Provider Type

Counsel

Subscribe to see more

Subscribe to see more

Service Type

General Counsel

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Novo Holdings Team

16 Team Members

Novo Holdings has 16 team members, including current Chief Executive Officer, Kasim Kutay.

Name

Work History

Title

Status

Kasim Kutay

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Kasim Kutay

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Novo Holdings to Competitors

Alexandra Instituttet Logo
Alexandra Instituttet

Alexandra Instituttet is an information technology consultant and developer. It provides artificial intelligence, digital green transition, cyber security, digital health, and more. It was founded in 1999 and is based in Aarhus, Denmark.

L
Luminary Therapeutics

Luminary is a clinical-stage allogeneic cell therapy company focused on combining advanced receptor design with cell engineering to overcome antigen escape and T-cell dysfunction. Its therapeutic solutions include BAFF CAR-T, Universal Receptor, and a non-viral allogeneic platform. The company was founded in 2019 and is based in Minneapolis, Minnesota.

Gilboa Therapeutics Logo
Gilboa Therapeutics

Gilboa Therapeutics operates as a preclinical-stage biopharmaceutical. It focuses on the development of novel, next-generation cancer immunotherapies designed to harness the power of a patient’s own immune system to treat cancer and improve outcomes. The company was founded in 2020 and is based in Rehovot, Israel.

H
Healios

Healios is a company focused on digital health, specifically within the neurology and clinical trials sectors. The company offers a digital health platform that utilizes digital biomarkers and remote monitoring to improve research for new treatments in neuroscience. These digital tools, such as smartphone and wearable devices, measure and collect health information, providing precise and objective measurements over long periods of time, primarily for the benefit of the clinical research and patient monitoring industries. It was founded in 2012 and is based in Basel, Switzerland.

I
Immunwork

Immunwork is a pharmaceutical company that focuses on the research, development, and commercialization of new drugs based on its technology platform for treating multiple types of cancer, autoimmune diseases, osteoporosis, and other severe clinical conditions.

Kelvin Health Logo
Kelvin Health

Kelvin Health is a company that operates in the healthcare sector, with a focus on leveraging artificial intelligence for health diagnostics. The company offers an intelligent solution for the detection and monitoring of various abnormalities and inflammation processes, using AI analysis applied to digital thermal imaging. This service is primarily targeted towards specialists in the healthcare industry. It was founded in 2020 and is based in Sofia, Bulgaria.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.